Rezolute Inc. (RZLT)
2.92
0.00 (0.00%)
At close: Mar 28, 2025, 3:59 PM
2.99
2.22%
After-hours: Mar 28, 2025, 06:32 PM EDT
0.00% (1D)
| Bid | 2.8 |
| Market Cap | 177.07M |
| Revenue (ttm) | 50.2K |
| Net Income (ttm) | -61.57M |
| EPS (ttm) | -1.32 |
| PE Ratio (ttm) | -2.22 |
| Forward PE | -4.32 |
| Analyst | Buy |
| Ask | 3.83 |
| Volume | 674,124 |
| Avg. Volume (20D) | 546,556 |
| Open | 2.98 |
| Previous Close | 2.92 |
| Day's Range | 2.89 - 3.03 |
| 52-Week Range | 2.22 - 6.19 |
| Beta | 0.96 |
About RZLT
Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, a selective and potent plasma kallikrei...
Industry Biotechnology
Sector Healthcare
IPO Date Jan 14, 2013
Employees 64
Stock Exchange NASDAQ
Ticker Symbol RZLT
Website https://www.rezolutebio.com
Analyst Forecast
According to 8 analyst ratings, the average rating for RZLT stock is "Buy." The 12-month stock price forecast is $12, which is an increase of 310.26% from the latest price.
Stock Forecasts6 months ago
+22.07%
Rezolute shares are trading higher after the compa...
Unlock content with
Pro Subscription
9 months ago
-23.45%
Rezolute shares are trading lower after the company announced a proposed public offering of common stock and pre-funded warrants.
